Mesoblast Limited - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 55 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Mesoblast Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Mesoblast Limited - Product Pipeline Review - 2014', provides an overview of the Mesoblast Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mesoblast Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Mesoblast Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Mesoblast Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Mesoblast Limited's pipeline products

Reasons to buy

- Evaluate Mesoblast Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Mesoblast Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Mesoblast Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Mesoblast Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mesoblast Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Mesoblast Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Mesoblast Limited Snapshot 5
Mesoblast Limited Overview 5
Key Information 5
Key Facts 5
Mesoblast Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Mesoblast Limited - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Mesoblast Limited - Pipeline Products Glance 13
Mesoblast Limited - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Mesoblast Limited - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Mesoblast Limited - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Mesoblast Limited - Drug Profiles 18
JR-031 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
remestemcel-L 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
MPC-150-IM 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
MPC-CBE 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Chondrogen 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MPC-06-ID 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MPC-25-Osteo 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MPC-MICRO-IO 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MSB-CAR-001 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MSC-300-IV 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Osteocel-XC 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Allogeneic Mesenchymal Precursor Cells for Asthma and Pulmonary Fibrosis 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Allogenic Mesenchymal Precursor Cells for Parkinson's Disease and Stroke 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Synthetic Peptide for Cardiovascular Diseases 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Mesoblast Limited - Pipeline Analysis 39
Mesoblast Limited - Pipeline Products by Target 39
Mesoblast Limited - Pipeline Products by Route of Administration 40
Mesoblast Limited - Pipeline Products by Molecule Type 41
Mesoblast Limited - Pipeline Products by Mechanism of Action 42
Mesoblast Limited - Recent Pipeline Updates 43
Mesoblast Limited - Dormant Projects 52
Mesoblast Limited - Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Tables
Mesoblast Limited, Key Information 5
Mesoblast Limited, Key Facts 5
Mesoblast Limited - Pipeline by Indication, 2014 8
Mesoblast Limited - Pipeline by Stage of Development, 2014 9
Mesoblast Limited - Monotherapy Products in Pipeline, 2014 10
Mesoblast Limited - Partnered Products in Pipeline, 2014 11
Mesoblast Limited - Partnered Products/ Combination Treatment Modalities, 2014 12
Mesoblast Limited - Pre-Registration, 2014 13
Mesoblast Limited - Phase III, 2014 14
Mesoblast Limited - Phase II, 2014 15
Mesoblast Limited - Phase I, 2014 16
Mesoblast Limited - Preclinical, 2014 17
Mesoblast Limited - Pipeline by Target, 2014 39
Mesoblast Limited - Pipeline by Route of Administration, 2014 40
Mesoblast Limited - Pipeline by Molecule Type, 2014 41
Mesoblast Limited - Pipeline Products by Mechanism of Action, 2014 42
Mesoblast Limited - Recent Pipeline Updates, 2014 43
Mesoblast Limited - Dormant Developmental Projects,2014 52
Mesoblast Limited, Subsidiaries 53